LustgartenLIVE!
Welcome to Lustgarten LIVE; our live-streamed webinar series created to introduce you to best-in-class experts from the field of pancreatic cancer research, technology, and science.
Each webinar in the series will focus on a different aspect of the research funded through your donations.
Hope is on the horizon!
REGISTRATION IS NOW OPEN
Learn how our LABS (Lustgarten Advancing Breakthrough Science) program fosters collaboration and accelerates breakthroughs in research from three of our six internationally renowned Lustgarten lab leaders — Tyler Jacks, PhD, Brian Wolpin, MD, PhD, and Reuben Shaw, PhD. Join us as they discuss the impact that their approaches are having, and the outcomes that could matter most for patients.
Thursday, December 12, 2024
Past LustgartenLive! Webinars
What the Future of Immunotherapy Could Mean for Pancreatic Cancer– Despite the success of immunotherapy in treating cancers like melanoma, lung cancer, and lymphoma, it hasn’t had the same impact on pancreatic cancer.
There is active research, led by Lustgarten, into overcoming these challenges, including combining immunotherapy with other treatments like chemotherapy, radiation, or novel agents that target the tumor microenvironment. Some promising approaches include vaccines that stimulate an immune response, CAR T-cell therapy specific to pancreatic cancer, and treatments that modify the tumor’s stroma or immune landscape to make it more susceptible to immune attack.
Join internationally renowned cancer immunotherapy and translational research expert, Robert H. Vonderheide, MD, DPhil, Director of the Abramson Cancer Center of the University of Pennsylvania for a one-on-one discussion with Lustgarten’s VP Research, Andrew Rakeman, PhD as they discuss future breakthroughs in this fast-growing field.
The Lustgarten Foundation believes that everyone deserves a seat at the table to help us achieve our mission of transforming pancreatic cancer into a curable disease.
Featured Speakers:
Linda Tantawi, CEO; Andrew Rakeman, PhD, Vice President of Research; David Tuveson, MD, PhD, Chief Scientist; Elizabeth Jaffee, MD, Chief Medical Advisor
Featured Sessions:
Clinical Trials: Where We Begin and Why (Sejin Chung, PhD); Clinical Trials: What is Underway at Johns Hopkins (Trish Brothers, BSN, RN, OCN and Beth Onners, RN, MSN); Genetics vs. Genomics (Dea Cunningham, RN, MSN); Cancer Vaccines (Sejin Chung, PhD and Beth Onners, RN, MSN)
Featured Sessions:
Early Detection and Interception: Harnessing New Technologies to Drive Better Outcomes (Brian Wolpin, MD; Sam Levy, PhD; Neeha Zaidi, MD); The Future is Now: Advancements in Treatment and Care; MRI-Guided Radiation Therapy and Tumor Treating Fields (Michael Chuong, MD); An Organoid for Predicting Neoadjuvant Therapy (Dan King, MD, PhD; Amber Habowski, PhD)
Featured Sessions:
The ‘Global Majority’: Encouraging Recruitment of Diverse Talent in BioPharma (Monique Phillips); Health Equity and Inclusion in the Research Community + Update on their Lustgarten-Funded Research (Avery Posey, Jr., PhD and Edwin Manuel, PhD); The Genomic Basis for Disparities in Pancreatic Cancer in African American Patients and Why This Lustgarten-Funded Study Represents an Important Milestone in Cancer Research (Howard Crawford, MD); Why Increasing Diversity in Clinical Trials Benefits All Patients (Nina Garambone, MPH, CCRC)
Featured Speakers:
David Tuveson, MD, PhD; Chief Scientist and Director, Lustgarten Foundation Dedicated Lab at Cold Spring Harbor Cancer Center; President, American Association of Cancer Research, Mark H. O’Hara, MD; Assistant Professor of Medicine, Hospital of the University of Pennsylvania, Eileen M. O’Reilly, MD; Winthrop Rockefeller Endowed Chair in Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Daniel A. King, MD, PhD; Director of Research and Development, Northwell Health Cancer Institute Center for Genomic Medicine, Domenech Asbun, MD; Hepatobiliary, pancreas and foregut surgeon, Miami Cancer Institute, Allyson J. Ocean, MD; Associate Professor of Clinical Medicine at Weill Cornell Medical College of Cornell University; Attending physician, New York-Presbyterian Hospital/Weill Cornell Medical Center.
- Multidisciplinary Care in Cancer Centers: Why it Matters with Katey Kennedy, 1440 Foundation; Christine A. Iacobuzio-Donahue, MD, PhD, Memorial Sloan Kettering Cancer Center; Danielle DePeralta, MD, Northwell Health Cancer Institute
- Seeing Beyond: New Horizons in Cancer Research with Nilofer Saba Azad, MD, Johns Hopkins Medicine; Jennifer J. Knox MSc, MD, FRCPC, Princess Margaret Cancer Center; Jen Jen Yeh, MD, UNC Medicine; Margaret Foti, PhD, MD, American Association of Cancer Research
- Lustgarten Foundation Career Development Award Lecture: In honor of Ruth Bader Ginsburg featuring Dannielle Engle, PhD, Salk Institute for Biological Studies
- Sharing the Journey: Fostering Growth Through Mentorship with Sommer Bazuro, PhD, FCB Health; Dannielle Engle, PhD, Salk Institute for Biological Studies; Elizabeth M. Jaffee, MD, Johns Hopkins Medicine; Jen Jen Yeh, MD, UNC Medicine; Rosalie Sears, PhD, Oregon Health & Science University; Margaret Foti, PhD, MD, American Association for Cancer Research.
The Best of 2021: Research Highlights, December 14, 2021 –Watch Lustgarten Foundation leadership for a special year-end review of the progress we’ve made toward transforming pancreatic cancer into a curable disease—and get a sneak peek into exciting research plans for 2022. Presenters include: David Tuveson, MD, PhD, Director of the Lustgarten Foundation Dedicated Research Lab at Cold Spring Harbor Laboratory (CSHL) Cancer Center; Elizabeth Jaffee, MD, Director, Lustgarten Clinical Accelerator Initiative; Linda Tantawi, CEO, Lustgarten Foundation; Andrew Rakeman, PhD VP of Research, Lustgarten Foundation. Watch now.
From the Lab to You: Clinical Advances, September 22, 2021 – World-renowned pancreatic cancer researchers and clinicians, Dr. Tyler Jacks of MIT and Dr. Brian Wolpin of the Dana-Farber Cancer Institute, explain Lustgarten’s critical role in moving research from the lab to the clinic, advancing clinical trials and better therapies. The Foundation established the Clinical Accelerator Initiative (CAI) to shorten the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science. These “smarter” clinical trials examine cutting-edge biomarkers to observe key indicators of how the treatment is working and will generate large volumes of data scientists can use now and in the future. We are funding three new clinical studies through the CAI focusing on immunotherapy to treat pancreatic cancer. Watch now.
Personalized Medicine: Transforming Treatment Wednesday, June 30, 2021 – Drs. David Tuveson, and Dennis Plenker of the Lustgarten Foundation Dedicated Pancreatic Cancer Research Lab at CSHL, and Dr. Wasif Saif, of Northwell Health Cancer Institute, take you from the clinic to the lab to show you how personalized medicine may transform the future of pancreatic cancer treatment. Watch now.
Early Detection: The Path Forward Wednesday, April 21, 2021 – Drs. Bert Vogelstein and Elliot Fishman of the Lustgarten Foundation Dedicated Pancreatic Cancer Research Laboratory at Johns Hopkins discuss how a blood test and artificial intelligence may impact earlier detection of pancreatic cancer. Watch now.